Johnson & Johnson to Post Q3 2024 Earnings of $2.12 Per Share, Zacks Research Forecasts (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ - Free Report) - Zacks Research reduced their Q3 2024 earnings per share estimates for Johnson & Johnson in a research note issued on Thursday, September 26th. Zacks Research analyst K. Shah now expects that the company will post earnings of $2.12 per share for the quarter, down from their prior estimate of $2.22. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.02 per share. Zacks Research also issued estimates for Johnson & Johnson's Q4 2024 earnings at $2.33 EPS, FY2024 earnings at $9.98 EPS, Q3 2025 earnings at $2.59 EPS, Q4 2025 earnings at $2.63 EPS, FY2025 earnings at $10.58 EPS, Q1 2026 earnings at $2.76 EPS, Q2 2026 earnings at $2.82 EPS and FY2026 earnings at $11.27 EPS.

Other equities analysts also recently issued reports about the stock. Daiwa America downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an "equal weight" rating in a report on Thursday, July 18th. TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating on the stock in a report on Thursday, July 18th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $173.21.

Johnson & Johnson Stock Up 0.0 %

Johnson & Johnson stock opened at $161.40 on Monday. The firm's 50 day moving average price is $162.15 and its two-hundred day moving average price is $154.16. The firm has a market cap of $388.44 billion, a PE ratio of 10.06, a P/E/G ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts' expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.80 EPS.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Wealth Partners LLC boosted its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after acquiring an additional 61 shares during the period. Citizens & Northern Corp boosted its stake in shares of Johnson & Johnson by 3.5% during the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company's stock valued at $275,000 after purchasing an additional 63 shares during the period. Epic Trust Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company's stock worth $268,000 after buying an additional 64 shares during the period. Pine Harbor Wealth Management LLC raised its holdings in Johnson & Johnson by 1.9% during the 2nd quarter. Pine Harbor Wealth Management LLC now owns 3,472 shares of the company's stock valued at $507,000 after buying an additional 64 shares during the last quarter. Finally, Outfitter Financial LLC boosted its position in Johnson & Johnson by 0.4% during the 2nd quarter. Outfitter Financial LLC now owns 16,632 shares of the company's stock valued at $2,431,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company's stock, valued at $3,131,683.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. Johnson & Johnson's dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.